Alkaloid has developed ready-to-use liquid Omeprazole. This drug is primarily designed to treat reflux esophagitis and GERD in young children unable to swallow tablets, as well as in adult patients who have difficulty swallowing and those with an inability to swallow. It is typically available in the form of gastro-resistant tablets and capsules, as well as powder for dissolution.
The product encloses two separate solutions in a dual-chamber package. Upon opening, these solutions automatically mix to provide ready-to-use liquid Omeprazole. The product has lemon and menthol flavor and is free from sugar, sorbitol, and artificial coloring, informed the company. A company statement disclosed, “To accommodate the specific requirements of this drug’s manufacturing process, the company invested in a custom-built machine tailored to this innovative product, ensuring an efficient and sustainable global supply chain.”
Alkaloid obtained the first international value-added medicine (VAM) patent for the Omeprazole peroral solution. The first marketing authorisations for this medication have been granted for both the Macedonian and UK markets. Registration processes are underway for European countries and European Union markets, with the anticipation of obtaining marketing authorisations and subsequent product launch.